Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis.

@article{Lange1998SelegilineII,
  title={Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis.},
  author={Dale J. Lange and Peregrine L Murphy and Beverly Diamond and Vicki Appel and Eugene C. Lai and David E. Sahn Stephen D. Younger and Stanley H. Appel},
  journal={Archives of neurology},
  year={1998},
  volume={55 1},
  pages={93-6}
}
BACKGROUND The cause of amyotrophic lateral sclerosis (ALS) is not known, and there is no effective treatment. Cell death may be caused by oxidative damage. Selegiline hydrochloride (Eldepryl) is a monoamine oxidase-B inhibitor with antioxidant properties. OBJECTIVE To determine if selegiline affects the clinical course of patients with ALS. DESIGN Six-month, double-blind, placebo-controlled study of 133 patients with classical ALS and symptoms for less than 3 years. The primary end point… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease.

Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases • 2008
View 10 Excerpts
Highly Influenced

Why is ALS so Difficult to Treat?

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques • 2014

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain. 1995;118:707-719

LJ Havercamp, V Appel, SH. Appel
ARCH NEUROL / VOL • 1998
View 1 Excerpt

Blood superoxide dismutase, catalase and glutathione peroxidase activities in familial and sporadic amyotrophic lateral sclerosis.

Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration • 1996
View 2 Excerpts

Management of patients with amyotrophic lateral sclerosis

DJ Lange, PL Murphy, RA Maxfield, A Skarvala, G. Reidel
J Neurol Rehab • 1994
View 1 Excerpt

Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis

WE Westarp, P Bartman, J Rossler
Neuroreport • 1993

Similar Papers

Loading similar papers…